drugset / Trial / NCT06510660
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2
Recruiting
48 enrolled
Fujian Medical University Union Hospital
Sun Yat-Sen University Cancer Center · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Timeline
- Start
- 2024-04-11
- Primary completion
- 2025-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |